CurrentEndo
Get Weekly

General medical journalCurrentEndo coverage

Nature Medicine

What CurrentEndo has captured from this journal. The coverage figures describe CurrentEndo's coverage, not the journal's output. Figures as of 14 November 2026.

CurrentEndo holds 100 Briefs from Nature Medicine, most often randomized controlled trials and cohort studies.

Recent
5 Briefs
past 90 days
Archive
100 Briefs
research published from January 2023 to today
Editorial
–
no Weekly issue published yet

Topics

Evidence types

Shares are of the 100 Briefs CurrentEndo has covered from Nat Med, by primary topic and study type; a Brief without a primary topic is in no topic row.

Publication activity

Latest from Nature Medicine

All coverage, newest first

  1. Nat Med

    Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial

    Randomized controlled trialObesity

  2. Nat Med

    Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial

    Secondary analysisObesity

  3. Nat Med

    Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial

    Randomized controlled trialObesity

  4. Nat Med

    Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial

    Randomized controlled trialT2D & other

  5. Nat Med

    Blood proteomics of menopause map to brain aging and dementia risk

    Diagnostic or prognostic studyReproductive endocrine

  6. Nat Med

    Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

    Randomized controlled trialObesity

  7. Nat Med

    Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants

    Secondary analysisT2D & other

  8. Nat Med

    Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

    Randomized controlled trialLipids & liver

  9. Nat Med

    Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

    Randomized controlled trialObesity

  10. Nat Med

    Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

    Randomized controlled trialObesity

  11. Nat Med

    Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

    Randomized controlled trialObesity

  12. Nat Med

    Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial

    Randomized controlled trialObesity

  13. Nat Med

    Data-driven prioritization of high-risk individuals for weight loss interventions

    Diagnostic or prognostic studyObesity

  14. Nat Med

    AI framework for multidisease detection via retinal imaging

    Diagnostic or prognostic studyT2D & other

  15. Nat Med

    Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial

    Secondary analysisObesity

  16. Nat Med

    Time-restricted eating for body weight management in women with polycystic ovary syndrome: a randomized controlled trial

    Randomized controlled trialReproductive endocrine

  17. Nat Med

    Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes

    Cohort studyT1D

  18. Nat Med

    Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

    Randomized controlled trialObesity

  19. Nat Med

    Genetic regulation across germline and somatic variation on the Y chromosome contributes to type 2 diabetes

    Research articleT2D & other

  20. Nat Med

    Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial

    Secondary analysisObesity

  21. Nat Med

    Circulating metabolites, genetics and lifestyle factors in relation to future risk of type 2 diabetes

    Cohort studyT2D & other

  22. Nat Med

    Multi-omic definition of metabolic obesity through adipose tissue–microbiome interactions

    Cohort studyObesity

  23. Nat Med

    The global macroeconomic burden of diabetes mellitus

    Research articleT2D & other

  24. Nat Med

    Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial

    Randomized controlled trialObesity

  25. Nat Med

    Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

    Cohort studyComplications

  26. Nat Med

    Data-driven subtypes of polycystic ovary syndrome and their association with clinical outcomes

    Cohort studyReproductive endocrine

  27. Nat Med

    Plasma proteome adaptations during feminizing gender-affirming hormone therapy

    Mechanistic studyReproductive endocrine

  28. Nat Med

    Obesity due to MC4R deficiency is associated with reduced cholesterol, triglycerides and cardiovascular disease risk

    Research articleObesity

  29. Nat Med

    A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults

    Meta-analysisObesity

  30. Nat Med

    Dietary profiles and associated metabolic risk factors in India from the ICMR–INDIAB survey-21

    Cross-sectional studyT2D & other

  31. Nat Med

    Prevention of type 2 diabetes through prediabetes remission without weight loss

    Secondary analysisT2D & other

  32. Nat Med

    Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity

    Cohort studyObesity

  33. Nat Med

    Genetic subtyping of obesity reveals biological insights into the uncoupling of adiposity from its cardiometabolic comorbidities

    Research articleObesity

  34. Nat Med

    Association between the English National Health Service Diabetes Prevention Programme and incident multiple long-term conditions

    Cohort studyT2D & other

  35. Nat Med

    Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency

    Secondary analysisObesity

  36. Nat Med

    DASH4D diet for glycemic control and glucose variability in type 2 diabetes: a randomized crossover trial

    Randomized controlled trialT2D & other

  37. Nat Med

    Ultraprocessed or minimally processed diets following healthy dietary guidelines on weight and cardiometabolic health: a randomized, crossover trial

    Randomized controlled trialObesity

  38. Nat Med

    Multimodal AI correlates of glucose spikes in people with normal glucose regulation, pre-diabetes and type 2 diabetes

    Cohort studyT2D & other

  39. Nat Med

    Polygenic prediction of body mass index and obesity through the life course and across ancestries

    Research articleObesity

  40. Nat Med

    Health effects associated with consumption of processed meat, sugar-sweetened beverages and trans fatty acids: a Burden of Proof study

    Meta-analysisT2D & other

All 100 Briefs in ExploreShowing the 40 most recently published